Sai Life Sciences Limited announced its unaudited financial results for the first quarter ended 30 June 2026 (Q1 FY27). The company reported strong growth across key financial metrics.

Financial Performance

  • Revenue from Operations: ₹554 crore in Q1 FY27, compared to ₹496 crore in Q1 FY26, representing a 12% year-on-year increase.
  • EBITDA: ₹148 crore in Q1 FY27, compared to ₹125 crore in Q1 FY26, an 18% year-on-year increase. This figure includes foreign exchange impact.
  • EBITDA Margin: 27% in Q1 FY27, compared to 25% in Q1 FY26.
  • Profit After Tax (PAT): ₹73 crore in Q1 FY27, compared to ₹60 crore in Q1 FY26, a 22% year-on-year increase.
  • PAT Margin: 13% in Q1 FY27, compared to 12% in Q1 FY26.

Business and Operational Highlights

  • The company operationalized a new 100,000 sq. ft. R&D facility at Genome Valley, Hyderabad.
  • Achieved EcoVadis Platinum Rating for sustainability, placing it in the top 1% of companies assessed worldwide.
  • Management commentary highlighted strong momentum across both CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) businesses.
  • CRO business grew 24% year-on-year.
  • The CMC (Chemistry, Manufacturing, and Controls) pipeline includes 33 active commercial molecules and 14 late-phase molecules.
  • The company emphasized its FTE-led engagement model, healthy balance sheet, and disciplined capital allocation.

Management Commentary

Krishna Kanumuri, Managing Director and CEO, stated that large pharmaceutical companies are seeking scientifically led partners for integrated discovery and development programs, and Sai Life Sciences is benefiting from this trend through strategic engagements that create a multi-year pipeline.

Siva Chittor, Chief Financial Officer, noted the healthy start to FY27 with growth across both business segments and expressed confidence in the company's long-term growth strategy.

Investor Communication

An earnings call is scheduled for August 7, 2026, at 4:00 PM IST to discuss the financial and business performance. Dial-in numbers and international toll-free numbers were provided for participation.